“According to the results from three studies published in European Urology, the 17-gene Oncotype DX Genomic Prostate Score is a significant predictor of disease aggressiveness at the time of diagnosis before intervention with radiation or surgery. The test provides more precise and individualized risk assessment than currently available tools and may help physicians choose the most appropriate treatment for their patients.”
Editor’s note: Newly diagnosed prostate cancer patients face complex treatment decisions based on many different factors. One major consideration is the level of aggressiveness of the cancer, i.e. how fast the cancer is likely to grow and metastasize. A test called the Oncotype DX Genomic Prostate Score examines 17 tumor genes to determine aggressiveness, and new research results show that the test is effective. Learn more about the test.